Judge Lets Former Pharmacy Director's Retaliation Suit Proceed
A federal magistrate judge in Indiana denied a motion to dismiss a False Claims Act retaliation case against a northwest Indiana hospital and foundation.
Updated on Nov. 6, 2026 in Healthcare
Magistrate Judge Abizer Zanzi of the U.S. District Court for the Northern District of Indiana denied a motion to dismiss a former pharmacy director's False Claims Act retaliation suit against Community Foundation of Northwest Indiana and St. Catherine Hospital. Kiriaki Koula Tsahas alleges she was fired for complaining about drug price fraud.
Why it matters
The ruling allows Tsahas's claims to move forward, with the court finding she sufficiently alleged protected activity under the False Claims Act. The case highlights scrutiny of how Indiana healthcare providers handle federal drug discount programs.
The court denied the defendants' motion to dismiss in its entirety, allowing the False Claims Act retaliation claim to proceed past the pleading stage. No dollar figures tied to the alleged 340B program irregularities were disclosed in the ruling summary, and the underlying merits remain unresolved.
The players
Kiriaki Koula Tsahas
Former pharmacy director who filed the retaliation suit alleging she was fired for complaining about drug price fraud.
St. Catherine Hospital
Northwest Indiana hospital named as a defendant in the False Claims Act retaliation lawsuit.
Community Foundation of Northwest Indiana
Northwest Indiana healthcare organization named as a defendant alongside St. Catherine Hospital in the suit.
Abizer Zanzi
U.S. Magistrate Judge in the Northern District of Indiana who denied the motion to dismiss in the case.
The details
Tsahas alleges she raised concerns about improper efforts to secure drug discounts under the federal 340B program before being terminated. The court found she had sufficiently alleged she engaged in activity protected under the False Claims Act, which is the threshold the defendants had challenged.
Timeline
Thursday, November 5, 2026: Magistrate Judge Zanzi issued the opinion denying the motion to dismiss.
Market Landscape
The False Claims Act's anti-retaliation provision, 31 U.S.C. § 3730(h), protects employees who report suspected fraud against the government, and this ruling applies it to complaints about the federal 340B drug discount program. Cases testing whether internal billing or pricing complaints qualify as protected activity have shaped how hospitals and pharmacy operators respond to whistleblowers.
Patients at hospitals that participate in the 340B program may see pricing and pharmacy practices scrutinized as the case moves forward. Employees who report billing or drug-pricing concerns in Indiana healthcare settings are protected under the False Claims Act's anti-retaliation provisions.
The takeaway
Whistleblower protections under federal law apply even when the underlying complaint concerns complex drug-pricing programs, and courts are willing to let such claims proceed past early motions. Healthcare workers who raise billing concerns should understand that the law offers recourse against retaliation.
Further reading
For more on how federal drug pricing programs shape hospital operations, see Healthcare coverage across the state.
Source note: This article includes information reported by Bloomberglaw.
